Understanding the role of PARP1 in blood disorders and targeted treatments
Official title: Implications of PARP1 in myelodysplastic syndromes and targeted therapy
Funded at University of Minnesota · NIH-11080877 · Data updated 2026-11-12
This study is looking at how certain gene changes in myelodysplastic syndromes (MDS) affect blood cell production and how a protein called PARP1 helps fix DNA damage, with the goal of finding new treatments that might help patients with MDS.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project start | May 20, 2022 |
| Project end | April 30, 2027 |
| Funding year | 2025 |
| Award (this year) | $512,269 |
| NIH project number | 5R01HL163011-04 |
| Project ID | NIH-11080877 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with myelodysplastic syndromes, particularly those with mutations in RNA splicing factor genes.
✕Less likely to help
Patients without myelodysplastic syndromes or those with other unrelated blood disorders may not benefit from this research.
What this research studies
This research investigates myelodysplastic syndromes (MDS), which are disorders caused by ineffective blood cell production due to mutations in specific genes. The study focuses on how these mutations lead to genomic instability and the role of PARP1 in managing DNA damage associated with these mutations. By exploring the relationship between R-loops and PARP1, the research aims to identify new treatment strategies that could target these vulnerabilities in patients with MDS. Patients may be involved in trials assessing the effectiveness of PARP inhibitors as a potential therapy.
Why it matters
Potential benefit: If successful, this research could lead to new targeted therapies for patients with myelodysplastic syndromes, improving their treatment outcomes.
How similar studies have gone: Previous research has shown promising results in targeting similar genetic vulnerabilities in blood disorders, suggesting that this approach may be effective.
Where this research is happening
-
University of Minnesota
Minneapolis, United States Active
Researchers
- Principal investigator: Nguyen, Dang Hai — University of Minnesota
- Study coordinator: Nguyen, Dang Hai
Related research
Other NIH-funded projects on the same topics.
-
PARP1 and targeted treatment for myelodysplastic syndromes
This work tests whether blocking a protein called PARP1 can help people with myelodysplastic syndromes who have certain RNA splicing gene mutations.
-
Integrative histo-genomic analysis to guide cancer risk and targeted therapies with interpretable AI
Researchers are developing an advanced AI-powered approach to map genetic and cellular patterns across breast and cervical cancers to help tailor treatments.
-
Targeted therapy for AML using DHODH inhibitors to boost differentiation and immune response
Aims to help adults with acute myeloid leukemia by using a special drug approach that makes cancer cells act more like normal blood cells and supports the immune system.
-
Adipome biomarkers in obese TNBC mice for targeted therapy
A study in mice explores how fat-derived particles called adipomes influence an aggressive breast cancer type, with the goal of guiding personalized therapies.
-
Enhancing HER2-targeted therapy for resistant breast cancer
This grant explores new ways to overcome resistance to HER2-targeted therapy in people with HER2-positive breast cancer.
-
Interferon-γ plus donor immune cells to fight AML/MDS after partial donor transplant
This project tests a therapy that adds a signaling protein, IFN-γ, with donor immune cells to help treat relapsed AML/MDS after a haploidentical stem cell transplant.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.